Digital Diagnostics Offers New Designation for Senior Executives | News

In the press release, Digital Diagnostics provides a new designation for senior executives, published 13-Jan-2022 per Digital Diagnostics on PR Newswire, the release has been updated with additional information. The complete and corrected version is as follows:

Digital Diagnostics offers new designation for senior executives

Co-founder titles added to recognize the impact of business leaders

CORALVILLE, Iowa, January 19, 2022 /PRNewswire/ — Digital Diagnostics recently announced the appointment of the company’s CEO and President/COO co-founder, Jean-Bertrand and Seth Rainford, respectively, after confirmation by the Board of Directors. The new designations follow the company’s renaming from IDx Technologies to Digital Diagnostics, and significant growth from a standalone AI diagnostics company focused on eye disease, to a standalone AI platform complete. The platform opens up future capabilities for diagnosing hundreds of diseases and improving outcomes for a wide range of patients. These C-suite updates recognize the growth plans and innovations of a company that seeks to advance the use of AI in other clinical applications.

“John and Seth have a vision to make Digital Diagnostics a world-class leader in healthcare diagnostics,” said Michael Abramoff, MD, PhD, Founder and Executive Chairman of Digital Diagnostics. “I created autonomous AI and our first product, IDx-DR, to improve productivity and access to healthcare and reduce health disparities. As a retina specialist, I have recognized the diabetic eye care gap leading to patients presenting with permanent vision loss This could have been avoided IDx-DR is the solution to making diabetic eye screening available at the point of care. The three of us are now extending this diagnostic platform beyond the eye to fill more gaps in care for a variety of disease states, which is the foundation of Digital Diagnostics. I am honored that the board of Directors has accepted my proposal to appoint John and Seth as co-founders, because IDx-DR is just the beginning, and we have an aggressive product development roadmap ahead of us to expand point-of-care diagnostics of service in all spec bedridden. »

Flagship product of Digital Diagnostics, IDx-DR, is the stand-alone AI diagnostic system for the detection of diabetic retinopathy and diabetic macular edema at the point of care. The product is the first autonomous AI authorized by the FDA in the field of health. Building on the ethical principles established during the creation and validation of IDx-DR, Digital Diagnostics continues to be guided by a mission to transform the quality, accessibility, equity and affordability of health care.

Bertrand and Rainford understand and embrace the complex ecosystem that healthcare is made up of, from patients, payers and providers to government agencies, healthcare systems, academics and private entities.

“We are working on the wide adoption of autonomous AI designed and built the right way to enable the advancements healthcare needs to ultimately improve the entire system, with patient outcomes at the core. forefront of this mission,” Rainford said. “Our company also recognizes that increased distribution of IDx-DR and a deep product development pipeline are critical to future advancements in Digital Diagnostics.”

“Seth and I remain rooted in the company’s vision to remove barriers to healthcare for patients and improve outcomes,” said Bertrand. “We know what it takes to make AI the right way at scale. As we look to the future, we remain a scientifically rigorous organization with a dedicated heart to putting patient outcomes first. .”

About Digital Diagnostics Inc.

Digital Diagnostics Inc. is a pioneering AI-powered diagnostics company whose mission is to transform the quality, accessibility, equity and affordability of global healthcare through the application of technology in the process of diagnosis and medical treatment. The company, originally founded by Michael Abramoff, MD, PhD, neuroscientist, fellowship-trained retina specialist, and computer engineer, is led in partnership with co-founders, Jean-Bertrand, and Seth Rainford. Today, the Digital Diagnostics platform includes two standalone AI systems, IDx-DR and DermSpot.

Digital Diagnostics is paving the way for autonomous AI diagnostics to become a new standard of care, helping to democratize healthcare and close care gaps. The company is working closely with patient advocacy groups, federal regulators, and other quality-of-care and ethics-focused stakeholders to enable the adoption of autonomous AI. For more information and the latest news, follow:

Show original content to download multimedia:

SOURCE digital diagnosis

Comments are closed.